Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT05748483

Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine (ATO-TOPIRAMATE)

A Randomized, Double-Blind, Parallel-Group, Active Controlled Trial With Open-Label Safety Extension to Evaluate the Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Subjects Requiring Preventive Treatment of Migraine (TEMPLE)

Sponsor: AbbVie

Conditions Migraine

Interventions Atogepant Placebo for Atogepant Placebo for Topiramate Topiramate

Updated 17 times since 2023 Last updated: May 21, 2025 Started: Oct 7, 2023 Primary completion: Apr 28, 2025 Completion: May 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Migraine and is currently ongoing. AbbVie leads this study, which shows 17 recorded versions since 2023 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

17 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting PHASE3
Jun 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE3
Dec 2024 — Jun 2025 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Oct 2024 — Dec 2024 [monthly]

Recruiting PHASE3
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE3

▶ Show 12 earlier versions

Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE3
May 2024 — Jun 2024 [monthly]

Recruiting PHASE3
Apr 2024 — May 2024 [monthly]

Recruiting PHASE3
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE3
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE3
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE3
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE3
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Sep 2023 — Nov 2023 [monthly]

Not Yet Recruiting PHASE3
Jul 2023 — Sep 2023 [monthly]

Not Yet Recruiting PHASE3
Mar 2023 — Jul 2023 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Almada, Portugal , Bad Homburg, Germany , Beersheba, Israel , Berlin, Germany , Bielefeld, Germany , Braga, Portugal , Brampton, Canada , Bristol, United Kingdom , Bron, France , Bruges, Belgium and 59 more locations